X Save
GO
Loading...

Enter multiple symbols separated by commas

Top News & Analysis

Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.
David Paul Morris | Bloomberg | Getty Images

Best of CNBC

The Big Crunch

Investing

Wall Street

Technology

Economy

Energy

Trading Nation

Must watch

Health Care

Wealth

Commentary

Real Estate

Personal Finance

Retail

Media

Small Business

Markets